ES104

Phase 2Small molecule

EElpiscience (Suzhou) Biopharma, Ltd.

ES104 is one of 44 small molecule programs targeting Metastatic Colorectal Cancer. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Metastatic Colorectal CancerActive, not recruiting

Metastatic Colorectal CancerPhase 2

Active, not recruiting

Competition

Competitive Landscape

159 competitors in Metastatic Colorectal Cancer

#DrugCompanyPhaseTrials

Camptosar

Pfizer

Phase 3

52 2

Keytruda

Merck & Co.

Phase 3

20 3

Wellcovorin

EEastern Cooperative Oncology Group

Phase 3

63 4

Opdivo

Bristol-Myers Squibb

Phase 3

13 5

Braftovi

Pfizer

Phase 3

12 6

Tecentriq

Roche

Phase 3

10 7

Yervoy

Bristol-Myers Squibb

Phase 3

7 8

Lumakras

Amgen

Phase 3

2 9

Bayer Aspirin

Bayer

Phase 3

2 10

Folinic Acid

Roche

Phase 3

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Metastatic Colorectal Cancer1 trial

A Study of ES104 in Patients With Metastatic Colorectal Cancer

Active, not recruiting·EElpiscience (Suzhou) Biopharma, Ltd.·Phase 1/2·NCT05167448·58 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for ES104. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — ES104 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for ES104. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Elpiscience (Suzhou) Biopharma, Ltd. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: EElpiscience (Suzhou) Biopharma, Ltd.

ES104

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Metastatic Colorectal Cancer1 trial

References

Drug Info

Quick Facts

Related News